EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Skye Bioscience's enterprise value is $9.35 Mil.
Skye Bioscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Skye Bioscience's EV-to-Revenue for today is .
The historical rank and industry rank for Skye Bioscience's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Skye Bioscience was 449.28. The lowest was -7.27. And the median was 22.27.
SKYE's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.38 * Ranked among companies with meaningful EV-to-Revenue only.
As of today (2025-05-28), Skye Bioscience's stock price is $1.99.
Skye Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00. Therefore, Skye Bioscience's PS Ratio for today is .
Skye Bioscience EV-to-Revenue Historical Data
The historical data trend for Skye Bioscience's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Skye Bioscience's EV-to-Revenue
For the Biotechnology subindustry, Skye Bioscience's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Skye Bioscience's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Skye Bioscience's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Skye Bioscience's EV-to-Revenue falls into.
Skye Bioscience's current Enterprise Value is $9.35 Mil.
Skye Bioscience's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience's share price for today is $1.99.
Skye Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Skye Bioscience EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Skye Bioscience's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SKYE has been successfully added to your 